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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Several anti-viral drugs are approved for the treatment of hepatitis
B virus (HBV) infection. However, whether quantitative hepatitis B surface antigen (qHBsAg)
can predict the therapeutic response during long-term entecavir treatment remains unclear.
Methods: Fifty-five chronic hepatitis B (CHB) patients who received entecavir for more than 2
years were enrolled. The serum qHBsAg level was measured by HBsAg II quant immunoassay. A
significant decline in the qHBsAg level was defined as > 1 log reduction from baseline to 6
months of entecavir treatment.
Results: Of the 55 patients (41 males and 14 females with a mean age of 48.3  11.4 years),
23 patients were positive for hepatitis B e antigen (HBeAg). The median treatment period
was 34 months, and ranged from 26 months to 43 months. A total of 288 serum samples were
used to determine the qHBsAg levels. At year 3 of entecavir therapy, one (1.8%) patient had
HBsAg seroclearance. A high qHBsAg level was defined as greater than 10,000 IU/mL. Patients
with a high baseline qHBsAg level had a lower rate of virologic response at year 1 (37.5% vs.
89.7%, p < 0.001) and year 2 (56.2% vs. 94.9%, p Z 0.001). In this study population, 14.5%
had a significant decline of the qHBsAg level. A significant decline could not predict HBeAg loss
in HBeAg-positive or virologic response in all patients.Chi Hospital, Buddhist Tzu Chi Medical Foundation, 289 Jianguo Road, Xindian Area, New Taipei City,
.tw (H.H. Lin).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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Quantitative hepatitis B surface antigen in entecavir treatment 787Conclusion: The baseline serum qHBsAg level can predict virologic response in entecavir-
treated CHB patients. However, a significant decline in the qHBsAg level cannot predict sero-
logic or virologic response of entecavir treatment.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hepatitis B virus (HBV) infection affects about 350 million
people and is the tenth leading causes of death in the
world.1 Its complications include cirrhosis, hepatic failure,
and hepatocellular carcinoma (HCC), leading to more than
600,000 premature deaths annually.2 Although new HBV
infection can be effectively prevented by hepatitis B
vaccination, the existing chronic hepatitis B (CHB) patients
continue to be a health burden worldwide. Interferon-
based or antiviral therapies have recently been proven to
decrease hepatic inflammation and reduce the develop-
ment of hepatic complications in patients with chronic HBV
infection.3
Entecavir (ETV) is a nucleoside analogue used for the
treatment of CHB. Previous studies have proven its efficacy
in HBeAg-positive and HBeAg-negative CHB patients.4e6
Better histological improvement, higher rate of undetect-
able serum HBV DNA, and normalization of serum alanine
aminotransferase (ALT) were noted at 48 weeks of therapy
with ETV in comparison to lamivudine (LMV) therapy.
However, the hepatitis B e antigen (HBeAg) seroconversion
rate was similar between ETV and LMV in HBeAg-positive
CHB patients. Because of the minimal risk of developing
resistance to ETV, several guidelines have recommended
the drug as a first-line agent for the treatment of CHB.7,8
In 1965, hepatitis B surface antigen (HBsAg) was initially
identified and named “Australia antigen”.9 This finding
subsequently contributed to the identification of HBV. The
antigenic protein on the outer surface of HBV virion could
be used as the target for the development of serologic test
and effective vaccines. In the past decades, the HBsAg test
was only qualitative. In clinical practice, a positive result
indicates ongoing HBV infection. The HBsAg level has
recently been quantitatively measured by newly developed
techniques. The serum quantitative HBsAg (qHBsAg) level is
reportedly correlated with intrahepatic HBV DNA and with
covalently closed circular DNA (cccDNA) levels.10 The on-
treatment level or dynamic change of HBsAg is also an in-
dicator of treatment response in pegylated interferon (PEG
INF)-treated CHB patients.11,12 However, whether the ki-
netics of qHBsAg during entecavir treatment can predict
the treatment response remains unclear and deserves
further investigation.
Materials and methods
In 2003, the Bureau of National Health Insurance in Taipei,
Taiwan began a treatment program for CHB. To date, oral
agents such as lamivudine, telbivudine, or entecavir can
be reimbursed for 3 years in HBeAg-positive or HBeAg-
negative CHB patients, and reimbursed indefinitely incirrhotic patients. In this prospective study, patients were
recruited from the Buddhist Tzu Chi General Hospital be-
tween October 2007 and March 2009. The inclusion criteria
of eligible patients were the presence of HBsAg for at least
6 months. The patients should meet one of the following
criteria prior to receiving ETV at a dose of 0.5 mg daily: (1)
a serum alanine aminotransferase (ALT) level greater than
five times the upper limit of normal (ULN) in HBeAg-
positive patients; (2) a serum ALT level greater than 2
times the ULN and a serum HBV DNA level greater than
20,000 IU/mL in HBeAg-positive patients; (3) a serum ALT
level greater than two times the ULN, obtained twice in a
period of at least 3 months, and a serum HBV DNA level
greater than 2,000 IU/mL in HBeAg-negative patients; (4)
hepatic decompensation with documentation of a total
bilirubin level greater than 2 mg/dL or a prolonged pro-
thrombin time greater than 3 seconds, compared to a
normal control; or (5) cirrhosis with evidence of portal
hypertension such as splenomegaly or varices. All partici-
pants received regular follow-up at 3-month intervals
during entecavir treatment and hepatic ultrasound ex-
amination every 6 months.
The exclusion criteria consisted of coinfection with
hepatitis C virus or the presence of other known liver dis-
eases such as alcoholism or autoimmune or metabolic liver
disease. Each participant provided written, informed con-
sent. All patients agreed to have serum samples stored
before treatment, and at 3 months, 6 months, 1 year, 2
years, and 3 years after treatment. The sera were stored at
80C until tested. The HBV genotype, the status of serum
HBeAg, and the pattern of the precore or core promoter
region were determined at study entry. The serologic
response was defined as HBeAg loss and/or seroconversion
in HBeAg-positive CHB patients. The virologic response was
defined as an undetectable level of serum HBV DNA in
HBeAg-positive or HBeAg-negative CHB patients. Because
most patients continued ETV treatment at the end of this
study, the on-treatment response was adopted in the cur-
rent study. At the time of data analyses, 123 patients had
given informed consent. Of these, 67 patients received ETV
treatment for at least 2 years. Twelve (17.9%) patients
were excluded because of the lack of available data of
baseline qHBsAg levels. Fifty-five patients were recruited
for statistic analyses.Laboratory assays
The serum ALT level was measured by using the automated
method (Roche Analytics; Roche Professional Diagnostics,
Penzberg, Germany) with the UNL of 40 IU/mL. The serum
HBsAg, HBeAg, and anti-HBe were tested by commercial
enzyme-linked immunosorbent assays.
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polymerase chain reaction Cobas TaqMan HBV assay (Roche
Molecular Systems, Branchburg, NJ, USA) with the lower
detection limit at 60 IU/mL and the upper limit at
1.1  108 IU/mL. The genotypes of HBV were determined by
using a real-time polymerase chain reaction (PCR)-based
single-tube assay, as previously described.13 For HBV
genomic analysis, precore and core promoter genes were
amplified by PCR.14 Nucleotide sequences of the amplified
products were directly determined by using fluorescence-
labeled primers with a 3100 Automatic Sequencer
(Applied Biosystems, Foster City, CA, USA).
The Elecsys HBsAg II quant immunoassay (Roche Ana-
lytics; Roche Professional Diagnostics, Branchburg, New
Jersey, USA) was used to quantify the serum HBsAg level,
according to the manufacturer’s instructions. This is a one-
step sandwich assay: the HBsAg in the samples is bound to
an antibody to HBsAg (anti-HBs) and streptavidin-coated
microparticle. The chemiluminescence reaction was initi-
ated by applying a voltage to the sample solution to detect
the reaction complex. The analyzer automatically per-
formed the on-board dilution. The range of measurement
was 0.05e52,000 IU/mL.
Endpoints
The primary endpoint of this study was to understand the
kinetics of the qHBsAg level in patients receiving ETV
treatment. The secondary endpoint was to elucidate theTable 1 Baseline characteristics of the chronic hepatitis B coh
HBeAg() (n Z 3
Age (y; age range) 52.0  10.0 (31.9
Sex
Female 8 (25.0)
Male 24 (75.0)
Cirrhosis
No 15 (46.9)
Yes 17 (53.1)
Baseline HBV DNA level (log10 IU/mL) 5.2  1.5
Baseline ALT level (U/L) 103.8  83.1
Baseline qHBsAg level (log10 IU/mL),
median (range)
3.3 (1.9e5.3)
HBV genotype
B 22 (68.8)
C 1 (31.2)
Precore
Wild 3 (9.4)
Mutant 27 (84.4)
Undetermined 2 (6.3)
Basal core promoter
Wild 15 (46.9)
Mutant 17 (53.1)
Undetermined 0 (0.0)
Data are presented as n (%) or mean  SD.
ALT Z alanine aminotransferase; DNA Z deoxyribonucleic acid;
qHBsAg Z quantitative hepatitis B surface antigen; SD Z standard d
a Indicates a significant difference (p < 0.05).factors affecting the qHBsAg level and the significant
decline of qHBsAg.
Ethical considerations
The study was performed in accordance with the principles
of the 1975 Declaration of Helsinki and approved by the
Ethical Committee of Buddhist Tzu-Chi General Hospital
(98-IRB-018-X). Each participant provided written,
informed consent.
Statistical analysis
Continuous variables were expressed as the mean and the
standard deviation or as the median and the range. They
were analyzed with a t test. Categorical variables were
included by using the frequency table and the Chi-square
test. A p value <0.05 was considered statistically
significant.
Results
Baseline demographics and background
characteristics
Table 1 summarizes the baseline clinical and virologic
characteristics of 55 CHB patients [41 males (74.6%) and 14
females (25.4%)]. The mean age at enrolment wasort.
2) HBeAg(þ) (n Z 23) p
e80.8) 43.1  11.4 (25.8e69.0) 0.004a
6 (26.1)
17 (73.9) > 0.99
18 (78.3)
5 (21.7) 0.026a
7.3  1.5 <0.001a
144.8  339.8 0.004a
4.2 (1.7e5.8) 0.002a
14 (63.6)
8 (36.4) 0.773
15 (68.2)
7 (31.8)
0 (0.0) < 0.001a
12 (54.6)
9 (40.9)
1 (4.5) 0.3957
HBeAg Z hepatitis B e antigen; HBV Z hepatitis B virus;
eviation.
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receiving treatment for hepatocellular carcinoma and
seven patients had used LMV. The median treatment period
was 34 months (range, 26e43 months). Of the 55 patients,
23 patients were HBeAg-positive and 32 were HBeAg-
negative. For qHBsAg levels, 288 samples were analyzed.
In one (1.8%) patient, HBsAg seroclearance was noted at
year 3 of ETV therapy.
Comparison of baseline characteristics between
HBeAg-positive and HBeAg-negative CHB patients
HBeAg-positive patients were younger and had higher
serum ALT levels and higher baseline HBV DNA level,
compared to HBeAg-negative patients. The qHBsAg level
was higher in HBeAg-positive than in HBeAg-negative pa-
tients. The cirrhosis prevalence rate and precore mutation
of the HBV genome were higher in HBeAg-negative patients,
compared to HBeAg-positive patients. There was no dif-
ference between the two groups in sex, prevalence of HBV
genotypes, and basal core promoter mutant (Table 1).
Treatment outcomes in HBeAg-positive and HBeAg-
negative CHB patients
In HBeAg-positive patients, the rates of HBeAg loss at year 1
and year 2 were 21.7% and 47.8%, respectively. In HBeAg-
negative patients, the rates of virologic response (HBV DNA
<60 IU/mL) were 84.4% at year 1 and 93.7% at year 2. The
rate of virologic response at year 2 was significantly higher
in HBeAg-negative patients than in HBeAg-positive patients
(Fig. 1). One (1.8%) patient had HBsAg seroclearance at82.6(19/23)
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75(24/32)
93.7(30/32)
0
10
20
30
40
50
60
70
80
90
100
%
    HBeAg (+)                                   HBeAg (–)
BR
VR
SR
p = 0.026
Figure 1 The 2-year response of entecavir treatment in
HBeAg-positive and HBeAg-negative chronic hepatitis B pa-
tients. BRZ biochemical response (defined as normalized ALT
level after 2 years of entecavir treatment); HBeAgZ hepatitis
B e antigen; SR Z serologic response (defined as HBeAg loss
and/or seroconversion after 2 years of entecavir treatment);
VR Z virologic response (defined as undetectable HBV DNA
levels after 2 years of entecavir treatment).year 3 of entecavir therapy. This was a 35-year-old female
patient who was HBeAg-positive at baseline. The kinetics of
qHBsAg was 19,404 IU/mL at baseline; it decreased to
2.1 IU/mL after 6 months of ETV treatment and became
undetectable after 3 years of ETV treatment.
The dynamics of qHBsAg levels during entecavir
treatment
The baseline qHBsAg levels were higher in HBeAg-positive
patients than in HBeAg-negative patients (median 4.2
log10 IU/mL vs. 3.3 log10 IU/mL, respectively) (p Z 0.002).
In HBeAg-negative patients, the qHBsAg levels remained
stationary after entecavir treatment for up to 24 months.
By contrast, the qHBsAg levels declined rapidly after
3 months of entecavir treatment in HBeAg-positive pa-
tients, but remained stationary thereafter for up to 24
months (Fig. 2).
Baseline characteristics associated with a high
qHBsAg level and the impact of a high qHBsAg level
on treatment outcomes
A high qHBsAg level was defined as a level greater than
10,000 IU/mL. The patients with a high qHBsAg level were
younger and had a higher frequency of positive HBeAg. High
qHBsAg level was also correlated with high serum ALT and
HBV DNA levels. The patients with a high qHBsAg level
tended to have a lower frequency of cirrhosis, compared to
qHBsAg-negative patients (p Z 0.068). There was no dif-
ference in sex or distribution of HBV genotypes between
the two groups. After adjusting for age, sex, cirrhosis,
HBeAg status, serum ALT, and log HBV DNA levels, multi-
variate analysis showed that HBV DNA was the only inde-
pendent factor associated with higher qHBsAg levels (odds
ratio 4.08, 95% confidence interval 1.63e10.23; data not
shown). In regard to the ability of qHBsAg to predict
treatment responses, at year 1 patients with a high baseline
qHBsAg level had a worse virologic response, compared to
qHBsAg-negative patients (37.5% vs. 89.7%, respectively;
p < 0.001) and at year 2 (56.2% vs. 94.9%; p Z 0.001).0
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Figure 2 The dynamics of quantitative HBsAg levels during
entecavir treatment. Neg Z HBeAg-negative patients;
Pos Z HBeAg-positive patients.
Table 2 Clinical factors and outcome of treatment, according to baseline serum HBsAg levels  10,000 IU/mL.
Baseline qHBsAg 
10,000 IU/mL (n Z 16)
Baseline qHBsAg
<10,000 IU/mL (n Z 39)
p
Age (y; age range) 42.5  10.9 (27.1e59.0) 50.6  10.9 (25.8e80.8) 0.019a
Sex
Female 3 (18.8) 11 (28.2)
Male 13 (81.2) 28 (71.8) 0.734
HBeAg
Negative 3 (18.8) 29 (74.4)
Positive 13 (81.2) 10 (25.6) < 0.001a
ALT (U/L) 303.0  396.8 132.8  118.8 0.018a
HBV DNA (log10 IU/mL) 7.9  1.5296 5.3  1.3276 < 0.001a
Cirrhosis
No 13 (81.3) 20 (51.3)
Yes 3 (18.7) 19 (48.7) 0.068
HBV genotype
B 10 (66.7) 26 (66.7)
C 5 (33.3) 13 (33.3) > 0.99
Undetectable serum HBV DNA at 1 y
No 10 (62.5) 4 (10.3)
Yes 6 (37.5) 35 (89.7) < 0.001a
Undetectable serum HBV DNA at 2 y
No 7 (43.8) 2 (5.1)
Yes 9 (56.2) 37 (94.9) 0.001a
HBeAg loss at 1 y in HBeAg(þ) patients
No 11 (84.6) 7 (70.0)
Yes 2 (15.4) 3 (30.0) 0.618
HBeAg loss at 2 y in HBeAg(þ) patients
No 8 (61.5) 4 (40.0)
Yes 5 (38.5) 6 (60.0) 0.414
Data are presented as n (%) or mean  SD.
ALT Z alanine aminotransferase; DNA Z deoxyribonucleic acid; HBeAg Z hepatitis B e antigen; HBV Z hepatitis B virus;
qHBsAg Z quantitative hepatitis B surface antigen; SD Z standard deviation.
a Indicates a significant difference (p < 0.05).
790 C.-C. Wang et al.However, the 1-year and 2-year HBeAg loss rate were
comparable between patients with a high qHBsAg level and
qHBsAg-negative patients (Table 2).Baseline characteristics associated with significant
decline of qHBsAg at 6 months of therapy and its
impact on treatment outcomes
A significant decline of the qHBsAg level at 6 months was
defined as a greater than 1 log10 IU/mL reduction from
the baseline to 6 months of treatment. Eight patients
achieved a significant decline of qHBsAg at 6 months. Of
these patients, 6 patients were HBeAg-positive at base-
line. Two patients had HBeAg seroconversion after 2 years
of entecavir treatment. One patient subsequently ach-
ieved HBsAg loss at year 3. The baseline HBeAg status was
negative in two patients. Their HBV DNA levels were un-
detectable in both patients after 2 years of entecavir
treatment. Between patients with a significant decline in
the HBV DNA level and those without a decline, there was
no difference in age, sex, cirrhosis, or HBV DNA levels. A
significant decline of the qHBsAg level 6 months after
beginning entecavir treatment was associated with highbaseline levels of ALT and qHBsAg. A significant decline of
the qHBsAg level at 6 months could not predict 1-year or
2-year HBeAg loss in HBeAg-positive patients or the viro-
logic response in CHB patients receiving ETV treatment
(Table 3).Discussion
In this study, 55 CHB patients received ETV for at least 2
years. After 6 months of treatment, 14.5% of the patients
had a decrease of the qHBsAg level that was greater than 1
log10 IU/mL. A baseline qHBsAg level greater than
10,000 IU/mL was associated with a worse virologic
response. If the baseline qHBsAg level was less than
10,000 IU/mL, then virologic response could be achieved in
89.7% of patients at year 1 and 94.9% of patients at year 2.
A significant decline of the serum qHBsAg level cannot
predict virologic response or HBeAg loss. These findings
suggested that baseline qHBsAg level may serve as a pre-
dictor of virologic response in CHB patients receiving ETV
treatment. However, a significant decline of the qHBsAg
level could not predict both virologic and serologic re-
sponses in this study population.
Table 3 Clinical factors and therapeutic outcome associated with a significant decline in the serum HBsAg level (>1 log) at 6
months of entecavir treatment.
Significant
decline (n Z 8)
No significant
decline (n Z 47)
p
Age (y; age range) 44.8  13.6 (27.1e65.3) 48.8  11.0 (25.8e80.8) 0.389
Sex
Female 1 (12.5) 13 (27.7)
Male 7 (87.5) 34 (72.3) 0.664
HBeAg
Negative 2 (25.0) 30 (63.8)
Positive 6 (75.0) 17 (36.2) 0.057
ALT (U/L) 444.3  519.7 137.8  122.9 <0.001a
qHBsAg (log10 IU/mL) 4.1  0.8222 3.5  0.6922 < 0.001a
HBV DNA (log10 IU/mL) 5.1  2.3082 5.9  1.6857 0.112
Cirrhosis
No 6 (75.0) 27 (57.5)
Yes 2 (25.0) 20 (42.6) 0.454
Undetectable HBV DNA at 1 y
No 4 (50.0) 10 (21.3)
Yes 4 (50.0) 37 (78.7) 0.181
Undetectable HBV DNA at 2 y
No 2 (25.0) 7 (14.9)
Yes 6 (75.0) 40 (85.1) 0.604
HBeAg loss at 1 y in HBeAg(þ) patients (n Z 23)
No 5 (83.3) 13 (76.5)
Yes 1 (16.7) 4 (23.5) > 0.99
HBeAg loss at 2 y in HBeAg(þ) patients (n Z 23)
No 4 (66.7) 8 (47.1)
Yes 2 (33.3) 9 (52.9) 0.640
Data are presented as n (%) or mean  SD.
ALT Z alanine aminotransferase; DNA Z deoxyribonucleic acid; HBeAg Z hepatitis B e antigen; HBV Z hepatitis B virus;
qHBsAg Z quantitative hepatitis B surface antigen; SD Z standard deviation.
a Indicates a significant difference (p < 0.05).
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the therapeutic response was better in patients with a
baseline qHBsAg level less than 10,000 U/mL.15 Ninety-five
CHB patients were recently treated with ETV for 2 years;
60% of these patients were HBeAg-positive. The baseline
qHBsAg levels were useful in predicting the virologic
response to entecavir treatment in 57 HBeAg-positive CHB
patients. Using the area under the curve analysis, re-
searchers have found that a baseline cutoff qHBsAg level of
9550 IU/mL had the highest predictive value.16 Our study
showed similar findings in that a baseline qHBsAg level less
than 10,000 U/mL could predict a better virologic response
in CHB patients receiving ETV treatment. In addition, this
finding could be extrapolated to all CHB patients, regard-
less of the HBeAg status. Based on these lines of evidence,
the qHBsAg level should be routinely assayed in CHB pa-
tients prior to starting ETV treatment. If the serum qHBsAg
level was less than 10,000 IU/mL, the virologic response
could be approximately 90% at year 1 and thereafter. In
clinical practice, patients are advised to receive HBV DNA
quantification once yearly in treatment-naı¨ve CHB patients
during the follow-up period, if the economic conditions
allow this. For patients on anti-HBV therapy, measurement
of the viral load is recommended at 3 months in case of
primary treatment failure, at 6 months to obtain the statusof the initial virologic response, and every 6 months
thereafter. From our data, if the baseline qHBsAg level was
less than 10,000 U/mL, the viral load could be measured at
year 1 and once yearly thereafter because of the very high
rate of virologic response in these CHB patients. Thus, our
findings are clinically valuable. Because the measurement
of serum HBV DNA level is expensive, the cost of HBV DNA
monitoring could be reduced in this special population.
An earlier study of 28 HBeAg-positive CHB patients
receiving ETV therapy found that a reduction in the serum
qHBsAg levels greater than 1 log10 IU/mL from the baseline
level after 12 months of treatment was associated with a
significantly higher 1-year HBeAg loss rate.17 This was the
first study to seek the utility of the qHBsAg level in pre-
dicting HBeAg loss in CHB patients with ETV therapy.
However, the sample size was relatively small and 1-year of
entecavir treatment was suboptimal in clinical practice. A
study with larger sample size subsequently showed incon-
sistent results. They found that the early decline of qHBsAg
levels at 12 weeks and 24 weeks were not associated with
HBV DNA suppression or HBeAg seroconversion in ETV-
treated CHB patients.18 Therefore, further studies are
needed to clarify this important and interesting issue. Our
data showed that a significant decline of qHBsAg level
cannot predict virologic response in overall patients and
792 C.-C. Wang et al.HBeAg loss in HBeAg-positive patients. Thus, these results
could improve our understanding about the relationship
between the decline in the qHBsAg level and the response
to ETV treatment.
Serum qHBsAg levels are reportedly associated with
intrahepatic HBV DNA and cccDNA levels.10,19 It is also
correlated with serum HBV DNA levels.20 Previous studies
indicate that qHBsAg levels varied during different phases
of the natural history of HBV infection. For example, the
qHBsAg level is highest in the immune tolerance phase, and
lower during the immune clearance phase, and decreases
progressively after HBeAg seroconversion.21 The qHBsAg
levels are higher in HBeAg-positive patients than in HBeAg-
negative patients.22 Our study’s findings were consistent
with previous studies. After adjusting for age, sex,
cirrhosis, HBeAg status, serum ALT, and log HBV DNA levels,
multivariate analysis showed that HBV DNA was the only
independent factor associated with high qHBsAg levels
(odds ratio 4.08; 95% confidence interval, 1.63e10.23).
Therefore, the qHBsAg level was independently associated
with the HBV DNA level, after adjusting for possible con-
founding factors. Thus, the dynamic change in the qHBsAg
level in the natural history of HBV is similar to the change in
the HBV DNA level. These findings provide additional evi-
dence to improve our understanding about the change of
qHBsAg in the natural history of HBV infection.
Interferon-based therapy can result in a greater qHBsAg
decline, compared to treatment with nucleoside analogues
(NAs).23 Furthermore, the decline in the qHBsAg level is
reportedly limited to ETV-treated patients with a baseline
ALT level more than 2 times the ULN. In this study popu-
lation, 14.5% of patients had a decrease in the qHBsAg level
that was greater than 1 log10 IU/mL after 6 months of
treatment. Patients who had a significant decline in the
qHBsAg level also had a significantly higher baseline ALT
level, indicating the serum ALT levels may reflect the in-
tensity of host immunity to reduce the qHBsAg level.
The on-treatment measurement of the qHBsAg levels
was useful as stopping rules to identify the patients
receiving IFN-based therapy who had a low probability of
sustained response. Unnecessary economic burden and side
effects could thus be avoided.24 HBsAg seroclearance is the
ideal end-point, although it is rare in clinical practice,
especially in Asian patients undergoing NAs treatment.
Therefore, optimized end-points of NAs treatment, which
could ensure sustained response with a low risk of relapse,
are needed to prevent the likelihood of long term or even
life-long treatment, especially in HBeAg-negative CHB pa-
tients. However, whether the cut-off value of qHBsAg can
be identified as an optimized end-point of treatment needs
further investigation.
This study has several unique features. First, the qHBsAg
level was measured by the Elecsys method (Roche Profes-
sional Diagnostics), rather than by the Architect method
that has been used in previous studies. Automatic dilution
in the Elecsys method could avoid errors created by
custom-made dilution. Second, all sera samples were
stored within 1 hour in a refrigerator at 80 C to ensure a
good quality of serum proteins. Third, serial data of the
qHBsAg level from baseline up to 3 years were obtained.
Therefore, we could find the kinetics of qHBsAg during ETV
treatment. Fourth, our paper is the first Taiwanese paperdescribing the predictive value of qHBsAg levels in the
virological response of patients receiving entecavir ther-
apy, and provides further evidence to strengthen the utility
of the qHBsAg level during entecavir treatment.
However, a few limitations should be acknowledged.
First, the patient number was not large and the study
population included people at various stages of HBV infec-
tion; however, this real-world data could truly reflect the
utility of qHBsAg in clinical practice. Furthermore, because
patients with various stages of HBV infection were
recruited in this study, we had the advantage of under-
standing the whole picture of qHBsAg change at different
stages of HBV infection. Second, a German study found that
patients with a significant decline in the HBsAg level at
6 months of treatment had a higher rate of HBsAg sero-
clearance at 3 years with telbivudine treatment than pa-
tients without a significant decline in the HBsAg level.25
However, the impact of the qHBsAg level on HBsAg sero-
clearance during ETV treatment could not be determined in
this study because there was only 1 patient with HBsAg
seroclearance at year 3.
In conclusion, this real-world data provides further evi-
dence to confirm the association between the qHBsAg
levels and the HBV DNA levels. A baseline qHBsAg level
greater than 10,000 IU/mL is also associated with a sub-
optimal virologic response to ETV therapy. However, a sig-
nificant decline in the serum qHBsAg level cannot predict
the virologic response or HBeAg loss in patients receiving
ETV treatment. Therefore, a baseline serum qHBsAg level
should be measured prior to beginning ETV treatment and
can be used to predict virologic response in CHB patients.Acknowledgments
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